Warren Buffett’s revelation that his prostate cancer was diagnosed with the help of a prostate-specific antigen (PSA) test threatens to reignite controversy that the medical community hoped had been settled last year over the usefulness of the test. Michael Barry, HMS clinical professor of medicine at Massachusetts General Hospital, is quoted.
